Elisa de Carvalho

Elisa de Carvalho

Auto-generated profile, based on publicly available information

Elisa de Carvalho

Hospital da Criança de Brasília Brasília Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
LSLarissa Caetano Silva
Larissa Caetano Silva
RSRenata B.P. Melo Seixas
Renata B.P. Melo Seixas
ECElisa de Carvalho
Elisa de Carvalho
Silva LC, et al. Pediatr Gastroenterol Hepatol Nutr. 2020 May;23(3):286-296. https://doi.org/10.5223/pghn.2020.23.3.286

1 July 2019 in Jornal de Pediatria
Verified
Journal Article
Open access
GPGilda Porta
Gilda Porta
ECElisa de Carvalho
Elisa de Carvalho
Jorge Luiz Dos SantosJorge Luiz Dos Santos
Jorge Luiz Dos Santos
JGJorge Gama
Jorge Gama
CBCristian V. Borges
Cristian V. Borges
GHGabriel Hessel
Gabriel Hessel
This large study with a long-term follow-up aimed to evaluate the clinical presentation, laboratory findings, histological profile, treatments, and outcomes of children and adolescents with autoimmune hepatitis. The medical records of 828 children and adolescents with autoimmune hepatitis were reviewed. A questionnaire was used to collect anonymous data on clinical presentation, biochemical and histological findings, and treatments. Of all patients, 89.6% had autoimmune hepatitis-1 and 10.4% had autoimmune hepatitis-2. The female sex was predominant in both groups. The median age at symptom onset was 111.5 (6; 210) and 53.5 (8; 165) months in the patients with autoimmune hepatitis 1 and autoimmune hepatitis-2, respectively. Acute clinical onset was observed in 56.1% and 58.8% and insidious symptoms in 43.9% and 41.2% of the patients with autoimmune hepatitis-1 and autoimmune hepatitis-2, respectively. The risk of hepatic failure was 1.6-fold higher for autoimmune hepatitis-2. Fulminant hepatic failure occurred in 3.6% and 10.6% of the patients with autoimmune hepatitis-1 and autoimmune hepatitis-2, respectively; the risk was 3.1-fold higher for autoimmune hepatitis-2. The gamma globulin and immunoglobulin G levels were significantly higher in autoimmune hepatitis-1, while the immunoglobulin A and C3 levels were lower in autoimmune hepatitis-2. Cirrhosis was observed in 22.4% of the patients; biochemical remission was achieved in 76.2%. The actuarial survival rate was 93.0%. A total of 4.6% underwent liver transplantation, and 6.9% died (autoimmune hepatitis-1: 7.5%; autoimmune hepatitis-2: 2.4%). In this large clinical series of Brazilian children and adolescents, autoimmune hepatitis-1 was more frequent, and patients with autoimmune hepatitis-2 exhibited higher disease remission rates with earlier response to treatment. Patients with autoimmune hepatitis-1 had a higher risk of death.

2 November 2022 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
ATAna Paula Bastos Tavares
Ana Paula Bastos Tavares
LSLucas Belém Pessôa de Melo Guerra Seixas
Lucas Belém Pessôa de Melo Guerra Seixas
CJCaren Lopes Wanderlei Jayme
Caren Lopes Wanderlei Jayme
GPGilda Porta
Gilda Porta
RSRenata Belém Pessôa de Melo Seixas
Renata Belém Pessôa de Melo Seixas
ECElisa de Carvalho
Elisa de Carvalho
Bastos Tavares AP, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Nov;25(6):489-499. https://doi.org/10.5223/pghn.2022.25.6.489

10 March 2026 in Jornal de Pediatria
Verified
Journal Article
Open access
ECElisa de Carvalho
Elisa de Carvalho
MCMirta Elba Ciocca
Mirta Elba Ciocca
GPGilda Porta
Gilda Porta
NSNatascha Silva Sandy
Natascha Silva Sandy
CTCarlos Marcelo Timossi
Carlos Marcelo Timossi
JBJorge Abdon Bezerra
Jorge Abdon Bezerra
To review current evidence on early diagnosis and initial management of biliary atresia, highlighting advances achieved in recent decades and the persistent challenges that continue to influence clinical outcomes. Relevant literature was identified through structured searches of PubMed and other major biomedical databases, complemented by manual review of reference lists from key original studies, systematic reviews, and position papers addressing biliary atresia and neonatal cholestasis. Biliary atresia remains a highly time-critical disease in pediatric hepatology, with outcomes strongly determined by age at surgical intervention. Population-based screening strategies, particularly stool color card programs, have shown meaningful reductions in age at surgery in selected regions, although their effectiveness is highly dependent on healthcare system organization and follow-up capacity. However, acholic stools remain a valuable sign for clinicians. Laboratory biomarkers such as gamma-glutamyl transferase and matrix metalloproteinase-7 provide complementary diagnostic support. Imaging modalities and liver biopsy continue to play essential roles in the diagnostic work-up. However, several commonly used tests predominantly reflect advanced disease and may be less informative in the earliest stages. Evidence supporting postoperative adjuvant therapies remains heterogeneous, with ongoing controversies regarding their impact on long-term native liver survival. Despite important advances, early diagnosis of biliary atresia remains challenging in many settings. Integrating clinical vigilance with the judicious use of screening strategies, biomarkers, and diagnostic procedures is essential to optimize outcomes. Continued efforts are needed to refine early diagnostic pathways and to address persistent gaps in evidence, standardization, and access to specialized care.

1 July 2019 in Jornal de Pediatria (Versão em Português)
Verified
Journal Article
Open access
GPGilda Porta
Gilda Porta
ECElisa de Carvalho
Elisa de Carvalho
Jorge Luiz Dos SantosJorge Luiz Dos Santos
Jorge Luiz Dos Santos
JGJorge Gama
Jorge Gama
CBCristian V. Borges
Cristian V. Borges
GHGabriel Hessel
Gabriel Hessel

9 March 2026 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
MCMariana Pena Costa
Mariana Pena Costa
AFAlexandre Rodrigues Ferreira
Alexandre Rodrigues Ferreira
ARAdriana Teixeira Rodrigues
Adriana Teixeira Rodrigues
RARodrigo Rezende Arantes
Rodrigo Rezende Arantes
TQThais Costa Nascentes Queiroz
Thais Costa Nascentes Queiroz
EFEleonora Druve Tavares Fagundes
Eleonora Druve Tavares Fagundes
To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (12 IIIa, 1 IIIb), 1 (0.8%) type IV, 6 (4.5%) type VI, and 49 (37.1%) with type IX (28 IXa, 7 IXb, and 14 IXc). Type I patients presented earlier (4 months) and had more episodes of hypoglycemia at clinical presentation ( p < 0.001). Anthropometric data at admission revealed impaired growth, with a tendency toward short stature across the groups (median −2.06, −1.89, and −1.96 among type I, III, and IX respectively). The median body mass index (BMI) z ‐scores at admission for all three types were above +1. Only patients with type IX demonstrated significant improvement in height ( p = 0.007) and BMI ( p = 0.020) z ‐scores during follow‐up. Regarding laboratory tests, significant decreases were observed in total cholesterol, triglycerides, venous lactate and aminotransferases in patients with types I and IX. Hepatic GSDs are heterogeneous diseases. There is a significant height impairment with a troublesome trend to overweight and obesity, especially in type I. Although there is improvement in aminotransferases, cholesterol, and triglycerides with follow‐up, adherence to treatment remains a challenge.